UK markets close in 5 hours 52 minutes

NeuroSense Therapeutics Ltd. (NRSN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.34000.0000 (0.00%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 23.23M
Enterprise value 20.73M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)4.15
Enterprise value/revenue N/A
Enterprise value/EBITDA -1.86

Trading information

Stock price history

Beta (5Y monthly) 1.56
52-week change 3-29.47%
S&P500 52-week change 322.64%
52-week high 32.3300
52-week low 30.4000
50-day moving average 31.6363
200-day moving average 31.0631

Share statistics

Avg vol (3-month) 3313.82k
Avg vol (10-day) 3165.86k
Shares outstanding 517.33M
Implied shares outstanding 617.59M
Float 811.15M
% held by insiders 128.56%
% held by institutions 11.03%
Shares short (15 Apr 2024) 488.41k
Short ratio (15 Apr 2024) 40.44
Short % of float (15 Apr 2024) 40.62%
Short % of shares outstanding (15 Apr 2024) 40.51%
Shares short (prior month 15 Mar 2024) 435.08k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-152.74%
Return on equity (ttm)-602.40%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -13.28M
Net income avi to common (ttm)-11.28M
Diluted EPS (ttm)-0.8300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.64M
Total cash per share (mrq)0.17
Total debt (mrq)142k
Total debt/equity (mrq)N/A
Current ratio (mrq)0.84
Book value per share (mrq)-0.12

Cash flow statement

Operating cash flow (ttm)-8.45M
Levered free cash flow (ttm)-3.71M